ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01

Marseille, France, November 11, 2020 – ImCheck Therapeutics presented preliminary results from its ongoing EVICTION Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta (γδ) T cell-activating monoclonal antibody, in patients with advanced, relapsed/refractory cancers. The data from the first cohort of six solid tumor cancer patients treated with ICT01 monotherapy demonstrated dose-dependent and specific γ9δ2 T cell activation and trafficking out of the circulation without dose-limiting toxicities or related serious adverse events.

This press release is only available in Englisch